ClinicalTrials.gg
Not yet recruitingNCT07769632Updated Aug 19, 2026

Total Osteo-Cartilage Replacement for the Treatment of Osteoarthritis of Knee

An Early Phase 1 interventional study of Total osteo-cartilage replacement of the distal femur and proximal tibia, including medial and lateral meniscus. and allogenic bone and cartilage graft in Osteoarthritis (OA) of the Knee, sponsored by AlSalam Hospital. Not yet recruiting at 1 site in Bahrain. Open to participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by AlSalam Hospital · Early Phase 1, Interventional, and Treatment

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
45 Years to 70 Years
Sex
All
01

Study summary

Young patients who require total knee arthroplasty with metallic and plastic implants will undergo femoral condyle cartilage and top of the tibia with meniscus replacement. With the proposed surgery patients will have increased range of movements so that they can sit on the ground to fulfill their social was of life, which is not possible with the standard of care total knee replacement.

Read the detailed description

Detailed Description Procedure for the TOCR: A cruciate knee replacement requires less bone and soft tissue resection. A more normal transmission of the weight-bearing stresses is possible compared to other knee Measures of Treatment Compliance: None. Study Procedures and Guidelines: replacements. Preserving both cruciate ligaments mandates the correct tension on all ligaments. Bi-cruciate retaining (BCR) TKA is considered to show improved clinical function and kinematics.The standard technique of the Bi-cruciate retaining (BCR) TKA is described. The importance of retaining both the cruciate ligaments cannot be over emphasized. In TOCR both the cruciate ligaments retained are native. The Cruciate ligaments, particularly the Anterior Cruciate Ligament (ACL), are vital for knee proprioception, acting as specialized sensors that inform the brain about knee position, movement, and load. They contain mechanoreceptors that initiate reflex muscle contractions to stabilize the joint. In standard TKR both the cruciate are removed making the stability on the implants. Figure I gives the standard cuts of the Femur and Tibia using the routine instrumentation of the Bi-cruciate retaining (BCR) TKA. During regular TKR, the bone segments removed are discarded, and this will follow the same procedure as TOCR. TOCR uses standard instrumentation of the bi-cruciate retaining TKR. All the cuts and procedures are similar to the TKR. Instead of metallic and polyethylene implants, a custom-matched Allograft of the femoral cartilage and Tibial plateau will be performed. The Allograft will be fixed with 2 Acutrak 2, 7.5mm X 120mm long, in the femur and tibia. The menisci will be sutured to the capsule of the native joint. The custom-matched allografts will be obtained by MTF Biologics, New Jersey, USA.The surgeons will carry out the initial 10 cases, and the cost will be borne by the Patent. Will take liability medical insurance for the patients to be treated if there are any complications. If the TOCR fails patients will undergo standard TKR and will be covered by the Insurance and Sponsors. The failure of the procedure could be infection which will be treated by antibiotics on out patient basis. As postoperatively patients will have routine physical therapy to strengthen the muscles and proper gait training for one month. The there is a failure of union then a bone graft can be further augmented and worse is to take out the allografts and perform the standard Total knee replacement. All patients will be instructed to report immediately to the hospital if any side effects are noted. Depending on the adverse effects, patients will continue or stop further treatment. All patients without or with adverse events will be followed for 36 months from the time they were operated on. All Adverse Events (AEs) were noted at every visit and were graded based on the intensity (mild, moderate, or severe) and relevance (serious, non-serious). Standard cuts of the Femur or Tibia in TKR. Schematic image of the post fixation in TOCR. Cadaveric Allografts of the Femur and Tibial Plateau. FIGURE I: Standard cuts of the Femur or Tibia in TKR.FIGURE II: Schematic image of the post fixation in TOCR Cadaveric TOCR. Figure IV: Cadaveric Allografts of the Femur and Tibial Plateau after fixation. Post-surgery patients will have the routine mobilization protocol by physical therapy as for standard TKR.

02

Conditions studied

  • Osteoarthritis (OA) of the Knee

Browse trials for

Keywords

  • Osteoarthritis
  • Kellgran and Lawrence
  • Knee joint
  • Total knee Replacement
  • Allogenic graft
03

In context

Osteoarthritis

2,974 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's planned enrollment of 10 is below the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

This is the only study on the registry with AlSalam Hospital as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being between 45 and 70 years of age of either gender. (OAK is common in this Age group)
  • Diagnosed with OAK with Kellgren and Lawrence Grading III and IV.
  • No ligamentous laxity and varus or valgus deformity. (In standard TKR patients with ligamentous laxity Constrained Condylar Knee (CCK) with intramedullary stem is used).
  • Patients who wish to have an active lifestyle.
  • Agreeing to participate and signing voluntarily.

Exclusion criteria

Exclusion Criteria:

  • Previous knee surgery within six months.
  • Uncontrolled Diabetes Mellitus
  • Chronic Kidney Disease. (Patients on hemodialysis)
  • Metabolic bone disease. (Severe osteoporosis with T Score of -\<3.5)
  • Patients who will not consent to follow-up.
  • Mental disorders and drug dependency (Patients who cannot understand the consent or the procedure of the TOCR).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    For osteoarthritis of knee grade II and III

    Total Osteo Cartilage replacement will be replaced using allogenic bone and cartilage graft with meniscus

    Biological: Total osteo-cartilage replacement of the distal femur and proximal tibia, including medial and lateral meniscus. · Device: allogenic bone and cartilage graft

Interventions

  • BiologicalTotal osteo-cartilage replacement of the distal femur and proximal tibia, including medial and lateral meniscus.

    IN total knee replacement metallic and plastic implant is used but in this procedure allograft with bone, cartilage and meniscus will be used.

    Also known as: Allogenic, Femoral cartilage, Proximal Tibia

  • Deviceallogenic bone and cartilage graft

    In this study allograft will be used instead of metallic and plastic implants.

    Also known as: allogenic, bone, cartilage, meniscus, bone and cartilage graft

06

What researchers measure

Primary outcomes

  1. Assessment of Allograft in osteoarthritis of knee

    The outcome of the allograft will be assessed by union of the allograft with the native bone.

    Time frame: 36 months

  2. assessment range of movements using WOMAC (Western Ontario University McMaster Osteoarthritis Index) .

    pain=0-20, stiffness=0-8, physical function=0-68. a total WOMAC score is created by summing the items for all three subscales (max score 96).

    Time frame: 3,6,9,12, 18, 24 and 36 months.

07

Study locations

1 site
  • AlSalam Specialist Hospital
    Manama, 80278, Bahrain
    • Jamal Saleh, FRCS, · Contactdrjsaleh@gmail.com · +97336599999
    • Mir Sadat-Ali, FRCS, PhD · Contactdrsadat@hotmail.com · +97339309939
    • Dr Jamal Saleh, FRCS · Principal investigator
08

References and documents

Publications

  • Gelber PE, Erquicia JI, Ramirez-Bermejo E, Farinas O, Monllau JC. Fresh Osteochondral and Meniscus Allografting for Post-traumatic Tibial Plateau Defects. Arthrosc Tech. 2018 May 28;7(6):e661-e667. doi: 10.1016/j.eats.2018.02.010. eCollection 2018 Jun. PubMed 30013907 ↗
  • Kaarre J, Herman ZJ, Zsidai B, Grassi A, Zaffagnini S, Samuelsson K, Musahl V. Meniscus allograft transplantation for biologic knee preservation: gold standard or dilemma? Knee Surg Sports Traumatol Arthrosc. 2023 Sep;31(9):3579-3581. doi: 10.1007/s00167-022-07187-w. Epub 2022 Oct 7. No abstract available. PubMed 36205759 ↗
  • Southworth TM, Naveen NB, Tauro TM, Chahla J, Cole BJ. Meniscal Allograft Transplants. Clin Sports Med. 2020 Jan;39(1):93-123. doi: 10.1016/j.csm.2019.08.013. PubMed 31767113 ↗
  • Gross AE, Shasha N, Aubin P. Long-term followup of the use of fresh osteochondral allografts for posttraumatic knee defects. Clin Orthop Relat Res. 2005 Jun;(435):79-87. doi: 10.1097/01.blo.0000165845.21735.05. PubMed 15930924 ↗
  • Volkov M. Allotransplantation of joints. J Bone Joint Surg Br. 1970 Feb;52(1):49-53. No abstract available. PubMed 4314242 ↗
  • Gross AE, Silverstein EA, Falk J, Falk R, Langer F. The allotransplantation of partial joints in the treatment of osteoarthritis of the knee. Clin Orthop Relat Res. 1975 May;(108):7-14. doi: 10.1097/00003086-197505000-00003. PubMed 1139838 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — not decided yet

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: November 2026 to October 2027

Access criteria: will share later

Data sharing details ↗ · www.alsalam.care

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Of 58 phase 1 interventional studies under Osteoarthritis, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 47. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Aug 18, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07769632
Lead sponsor
AlSalam Hospital
Responsible party
Sadat A Ali (Consultant Orthopaedic and Arthroplasty sugeon, AlSalam Hospital) — Principal investigator
First posted
Aug 18, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Jamal Saleh, FRCS
Contact
drjslaeh@gmail.com
+97336599999
Mir Sadat-Ali, FRCS, PhD
study director · US Consultancy for Applied Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion